ClinicalTrials.gg
Enrolling by invitationNCT07127692Updated Jun 16, 2026

Prevalence of Sarcopenia-Promoting Medicines in Patients With Sarcopenia and Falls

An observational study in Sarcopenia in Elderly and Falls, sponsored by Medway NHS Foundation Trust. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Medway NHS Foundation Trust · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
100
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Sarcopenia with a site in United Kingdom — 11 open to participants now, 14 under way, none of them phase 3. Sarcopenia · United Kingdom.

Planned enrollment
13th of 22
100 · median 132
Started
2025
with 1 other
Observational
22 of 72
5 open now
Primary completion
2027-02
later than 9 of 13 live
Registered
69th of 72
by date

Among the 72 studies in Sarcopenia with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 22 observational ones that give a count, is one of 2 that started in 2025, is one of 22 observational ones, reaches primary completion later than 9 of the 13 other live ones, and was the 69th registered.

Sarcopenia

1,333 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

11 of the 72 studies in Sarcopenia with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Sarcopenia with a site in United Kingdom, or all of them as a file.
02

Study summary

Sarcopenia, characterised by the loss of muscle mass and function, is a common condition among the elderly and is often associated with increased risk of falls. Certain medications, such as glucocorticoids, statins, and some antipsychotics, may exacerbate sarcopenia, leading to a higher incidence of falls. This study aims to explore the prevalence of such medicines in patients diagnosed with sarcopenia who have experienced falls. Understanding the impact of these medications on sarcopenia and fall risk can inform clinical guidelines and improve patient outcomes.

Read the detailed description

Sarcopenia, the age-related loss of muscle mass and strength, is a recognised contributor to frailty, disability, and increased fall risk in older adults. While physical inactivity and comorbidities are known risk factors, increasing evidence suggests that certain medications - including corticosteroids, sedatives and statins - may also contribute to muscle decline. These medicines are frequently prescribed to older adults, but the extent of their use in patients with sarcopenia and falls remains poorly defined.

Falls clinics manage high-risk patients, yet there is currently limited research examining the prevalence of sarcopenia-promoting medications in this specific setting. This study addresses an important knowledge gap by estimating the prevalence of these medicines in older adults attending a secondary care falls clinic, and by exploring associations with sarcopenia and fall history.

The findings will support a better understanding of medication-related risk factors for sarcopenia and may help guide future deprescribing and medication review strategies. This aligns with current priorities in geriatric medicine to reduce inappropriate polypharmacy and improve outcomes for older adults through targeted, evidence-based prescribing.

03

Conditions studied

  • Sarcopenia in Elderly
  • Falls

Browse trials for

Keywords

  • Sarcopenia-promoting medicines
  • Sarcopenia
  • Falls
  • Medicines in elderly
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted in a multidisciplinary falls clinic at Medway NHS Foundation Trust, based in Gillingham, Kent, England, UK. This secondary care setting receives referrals primarily from inpatient hospital teams and primary care practitioners. The clinic routinely assesses older adults who have experienced falls or are at high risk of falling, and conducts comprehensive geriatric assessments, including medication reviews, functional status evaluations, and frailty assessments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥65 years
  • Attendance at the falls clinic for a new assessment
  • Diagnosed with sarcopenia (based on the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria)
  • History of falls in the past 12 months

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment preventing consent
  • Acute medical instability
  • Enrolled in on other clinical trials.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testStrength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire

    Self-administered screening tool for sarcopenia

  • Diagnostic testHand grip strength

    Used to assess sarcopenia

  • Diagnostic testTimed Up and Go test

    Screening test for falls in elderly

  • Diagnostic testGait speed

    Assessment to check for functional mobility and risk of falls.

  • Diagnostic testClinical Frailty Scale (CFS)

    Used to assess level of frailty.

06

What researchers measure

Primary outcomes

  1. Prevalence of exposure to one or more sarcopenia-promoting medication

    Proportion of adults aged 65 years and over attending the falls clinic who are prescribed one or more sarcopenia-promoting medication. Unit of measure: % of participants.

    Time frame: 6 months

Secondary outcomes

  1. Distribution of sarcopenia-promoting medication classes

    Proportion of participants exposed to each medication class. Unit of measure: % of participants per medication class.

    Time frame: 6 months

  2. Number of sarcopenia-promoting medications per participant

    Mean number of eligible medications prescribed per participant. Unit of measure: count.

    Time frame: 6 months

  3. Handgrip strength

    Mean maximum grip strength measured with a Jamar dynamometer. Unit of Measure: Kilograms (kg).

    Time frame: 6 months

  4. Gait speed

    Mean walking speed measured over 4 metres. Unit of measure: metres per second (m/s)

    Time frame: 6 months

  5. SARC-F score

    SARC-F mean score. Unit of measure: points (0-10)

    Time frame: 6 months

  6. Timed Up and Go Test

    Mean time taken to stand from a chair, walk 3 metres, turn, walk back and sit down. Unit of measure: Seconds (s).

    Time frame: 6 months

  7. Association between medication burden and functional performance

    Comparison of grip strength, gait speed, SARC-F scores and Timed Up and Go performance across groups defined by medication burden e.g. 0-1 vs \>2 sarcopenia promoting medications. Units of measure: Differences in mean values (kg, m/s, points, seconds).

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: Balancing evidence-based medicine against falls risk. Postgrad Med. 2015 Apr;127(3):330-7. doi: 10.1080/00325481.2014.996112. Epub 2014 Dec 24. PubMed 25539567 ↗
  • Veronese N, Stubbs B, Noale M, Solmi M, Pilotto A, Vaona A, Demurtas J, Mueller C, Huntley J, Crepaldi G, Maggi S. Polypharmacy Is Associated With Higher Frailty Risk in Older People: An 8-Year Longitudinal Cohort Study. J Am Med Dir Assoc. 2017 Jul 1;18(7):624-628. doi: 10.1016/j.jamda.2017.02.009. Epub 2017 Apr 7. PubMed 28396180 ↗
  • Tanskanen, A., et al. (2015). Anticholinergic burden and physical functioning in older people: A systematic review. Drugs & Aging, 32(10), 741-750.
  • Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017 May 16;16:21. doi: 10.1186/s40200-017-0302-x. eCollection 2017. PubMed 28523252 ↗
  • Scott, D., et al. (2016). Sarcopenia and statin use: A potential link? Drugs & Aging, 33(1), 1-9.
  • Reeve E, Wiese MD, Hendrix I, et al. (2014). The impact of deprescribing interventions on polypharmacy and clinical outcomes: a systematic review and meta-analysis. J Am Med Dir Assoc. 15(3):131-6. https://doi.org/10.1016/j.jamda.2013.11.008
  • Rawle MJ, Westbury LD, Russell S, et al (2018). Anticholinergic drug burden and cognitive function in people aged 50 years and older: the English Longitudinal Study of Ageing. Age Ageing; 47(4):505-11 https://doi.org/10.1093/ageing/afy026
  • Landi, F., et al. (2019). Polypharmacy and sarcopenia in older adults: A population-based study. Journal of the American Medical Directors Association, 20(5), 600-604.e7.
  • Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr. 2012 Oct;31(5):652-8. doi: 10.1016/j.clnu.2012.02.007. Epub 2012 Mar 11. PubMed 22414775 ↗
  • Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, Coulton S, Katona C, Boustani MA, Brayne C. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011 Aug;59(8):1477-83. doi: 10.1111/j.1532-5415.2011.03491.x. Epub 2011 Jun 24. PubMed 21707557 ↗
  • Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. No abstract available. PubMed 31081853 ↗
  • Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571-84. doi: 10.2174/092986710790416326. PubMed 20015034 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2025
First posted
Aug 17, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07127692
Lead sponsor
Medway NHS Foundation Trust
Responsible party
Kamaldeep Sahota (Lead Clinical Pharmacist Frailty, Medway NHS Foundation Trust) — Principal investigator
First posted
Aug 17, 2025
Start date
Sep 4, 2025
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Kamaldeep K Sahota, Pharmacist
principal investigator · Medway NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion